Gan & Lee Pharmaceuticals and Menarini have announced plans to collaborate on the registration and commercialisation of Gan & Lee’s glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide. The drug is under development for the treatment of adults with obesity or overweight, administered once every two weeks. … Read More
The US Food and Drug Administration (FDA) has approved Lilly’s Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE) in adults with type 2 diabetes. The drug is already approved as an adjunct to diet… Read More
New research has shown that people taking oral semaglutide – the active ingredient used in Wegovy – experienced fewer heavy-drinking days, consumed fewer drinks when they did drink and reported weaker everyday cravings than those given a placebo. The eight-week randomised clinical trial involved 50 adults with moderate-to-severe alcohol use… Read More
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron (Foundayo), making it the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and… Read More
Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies. The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. Read More
Eli Lilly has announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase III trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some… Read More
With the largest diabetic population and a pedigree in metabolic diseases, China is becoming one to watch in diabetes and obesity drug discovery. Diana Turner finds out about an increasingly competitive market. Research by clinical research organisation ICON in late… Read More
Janice MacLennan, Founder & CEO, Nmblr, explains why biopharma companies hoping to enter the competitive GLP-1 market need to build value narratives in parallel with scientific evidence. The emergence of GLP-1 therapies is unprecedented, with the global GLP-1 receptor agonist market valued at $66.4 billion in 2025 and projected to reach $185.3 billion by 20331. Read More
Is the honeymoon period over for GLP-1s or is the market yet to reach its full potential? Diana Turner asks what will differentiate the next generation of these peptide analogues. Glucagon-like peptide-1 (GLP-1)… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More
News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW. This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research. The top stories: … Read More
The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Vincent Marion, Scientific Founder and President of AdipoPharma. AdipoPharma is a biotech leveraging research on insulin resistance and adipose tissue biology, developing a new treatment for metabolic diseases. Vincent… Read More
The new Wegovy pill could help patients lose 17% of their body weight, clinical trial results show. The tablet version of Wegovy, approved in the UK by MHRA, is the first GLP-1 weight-loss pill licensed for weight management in the UK and is expected to become available… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research showed anti-IL-1β drugs could prevent lung cancer. Elsewhere, the… Read More
News round-up for 8 – 12 June by Bruno Quinney, Content Team at DDW. This week, new research suggests anti-IL-1β drugs could prevent lung cancer. Elsewhere, the UK is set to benefit from specialised blood tests and funding for researchers. The top stories: … Read More
